



Is it time to revise the International Association for the Study of Lung Cancer definitions of completeness of lung cancer resection?

Ramón Rami-Porta^{1,2^}, John G. Edwards³, Raymond U. Osarogiagbon^{4,5}

¹Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa, University of Barcelona, Terrassa, Barcelona, Spain; ²Network of Centres for Biomedical Research in Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Barcelona, Spain; ³Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, UK; ⁴Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee, USA; ⁵Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee, USA

Correspondence to: Ramón Rami-Porta, MD. Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa, Plaza Dr. Robert 5, 08221 Terrassa, Barcelona, Spain. Email: rramip@yahoo.es.

Comment on: Lee J, Hong YS, Cho J, *et al.* Reclassifying the International Association for the Study of Lung Cancer Residual Tumor Classification According to the Extent of Nodal Dissection for NSCLC: One Size Does Not Fit All. *J Thorac Oncol* 2022;17:890-9.

Keywords: Complete resection; International Association for the Study of Lung Cancer (IASLC); incomplete resection; lung cancer surgery; uncertain resection

Submitted Oct 19, 2022. Accepted for publication Nov 08, 2022.

doi: 10.21037/tcr-22-2426

View this article at: <https://dx.doi.org/10.21037/tcr-22-2426>

In a recent article published in the *Journal of Thoracic Oncology*, Lee *et al.* suggest that the International Association for the Study of Lung Cancer (IASLC) criteria for categorizing completeness of lung cancer resection should be revised and adapted to the pathologic type of the tumour, its biologic behaviour and its risk profile (1). Their conclusion is based on a detailed single tertiary care institution retrospective cohort study of 5,117 patients who had undergone complete (2,806 patients) or uncertain (2,311 patients) resections based on the IASLC definitions (2). Deconstructing their analysis cohort according to three lymph node evaluation criteria (adequate examination of mediastinal, hilar/intrapulmonary and subcarinal lymph nodes), they categorized resections meeting all three criteria as ‘fully compliant’ (meaning they met the IASLC definition of R0 resection; 2,806 patients), ‘partially compliant’ (met one or two, but not all three criteria; 1,959 patients), ‘noncompliant’ (did not meet any of the three criteria; 352 patients). The latter two groups

met IASLC criteria for uncertain resection [R0(un)]. They focused attention solely on the intraoperative nodal assessment because an inadequate nodal assessment by IASLC criteria, that is, less than the minimum requirements for systematic nodal dissection or lobe-specific systematic nodal dissection (2), was the criterion for reclassification from R0 (no residual tumour) resection, as judged by the Union for International Cancer Control (UICC) criteria (3), to R0(un) in 97.4% of patients.

The comparative recurrence free survival (RFS) and overall survival (OS) results were paradoxical: the partially compliant and noncompliant [R0(un)] cohorts had significantly better survival than the fully compliant (R0) cohort (*Fig. 2* in Lee *et al.*) (1). That is, patients in the cohorts with a less rigorous lymphadenectomy lived longer than those whose nodal assessment fulfilled the recommended requirements. Those significant differences held in the aggregate groups of patients and in the clinical stage I, and adenocarcinoma subsets (*Table 1*). RFS and

[^] ORCID: 0000-0003-3366-7664.

Table 1 Five-year survival of fully compliant, partially compliant and noncompliant groups

Survival	FCG	PCG	NCG	P value
Five-year survival: global				
RFS	69.7%	74.5%	86%	<0.001
OS	80.1%	84.5%	89.9%	<0.001
Five-year survival: clinical stage I				
RFS	75.2%	79.5%	87.5%	<0.001
OS	75.2%	87.2%	88.6%	<0.001
Five-year survival: adenocarcinoma				
RFS	86.3%	88.3%	96.9%	<0.001
OS	92.4%	95.3%	97.6%	<0.001

FCG, fully compliant group; PCG, partially compliant group; NCG, noncompliant group; RFS, recurrence free survival; OS, overall survival.

OS were worse in the noncompliant group with clinical stage II. Moreover, when adenocarcinomas with no lepidic component were analysed separately, OS did not differ among the three groups. Furthermore, when stratified according to pathologic stage, RFS and OS did not differ in the comparison of adenocarcinoma in situ (AIS) combined with minimally invasive adenocarcinoma (MIA), stages IA1 and IA2, but OS was significantly worse ($P=0.021$ for the 3-cohort comparison) in the noncompliant group with stage IA3 (Fig. S2 in Lee *et al.*) (1).

The authors recognize that major imbalances in key prognostic characteristics between the cohorts accounted for the appearance of better survival in the groups with inadequate nodal assessment. For example, 51.4% of patients in the noncompliant group had adenocarcinomas with lepidic component, compared to 13.3% and 22.6% of patients in the fully compliant and partially compliant groups, respectively ($P=0.001$); 20.3%, 2.5% and 4.9% of the non-, fully- and partially-compliant groups, respectively, were clinical stage IA1 ($P=0.001$); and 52.3%, 18.4% and 31.9%, respectively, were clinical stage IA2 ($P=0.001$); and pathologic stage I tumours were 91.5%, 58.2% and 75.2%, respectively ($P=0.001$). Consequently, the comparative wedge resection rates were 68.2%, 0.2% and 7.7%, respectively ($P=0.001$).

Given the foregoing, should we revise the IASLC definitions of completeness of lung cancer resection as the authors suggest? Is there sufficient evidence to support tailoring the definition to clinico-pathologic characteristics?

If so, what characteristics? A careful consideration of these questions is in order, starting with brief historical context. When the IASLC proposed the definitions of complete, incomplete and uncertain resections in 2005 (2), there was no universally accepted classification of lung adenocarcinomas. The Noguchi classification, the forerunner of the IASLC/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification, although published 10 years before the IASLC completeness of resection definition, was not universally applied, and hard evidence on the indolence and excellent long-term survival of Noguchi types A and B was lacking (4). A multidisciplinary group of specialists from the IASLC, the ATS and the ERS proposed a new classification of lung adenocarcinomas, including the new entities AIS, MIA and lepidic predominant adenocarcinoma, in 2011 (5), which was incorporated into the World Health Organization book of thoracic pathology in 2015 (6).

We now know that AIS and MIA have a postoperative disease-free survival of 100% (7,8), because, by definition, AIS does not invade surrounding tissues and MIA does not invade beyond 5 mm; AIS and MIA do not disseminate distally via haematogenous or lymphatic spread; and adenocarcinomas with lepidic component have better survival than other subtypes (9). Therefore, lymphadenectomy may be unnecessary for AIS and MIA, and the lack of the recommended systematic nodal dissection or lobe-specific systematic nodal dissection should not preclude a complete resection. However, the diagnosis of AIS and MIA requires pathologic examination of the whole specimen and frozen section examination may be inadequate. The concordance of frozen section and definitive pathologic diagnosis varies, seemingly dependent on the number of studied cases, that is, the experience of the pathologist. He *et al.* reported a concordance of 63.24% in a series of 136 patients (10). The concordance reported by Shima *et al.* was 82.7% in 151 patients (11). With 803 patients, Liu *et al.* reported a concordance of 84.4% (12). Su *et al.* and Zhang *et al.* with 2,006 and 3,031 patients, respectively, reported the highest concordance of 86.4% and 93.7%, respectively (13,14). AIS and MIA of ≥ 1 cm are at risk of being upstaged at definitive pathologic examination to invasive adenocarcinomas, and, if no further treatment is indicated (completion lobectomy or anatomical segmentectomy, if not performed, or adjuvant chemotherapy, if appropriate), local recurrence is possible (13). Although others have reported 100% 5-year disease-free survival for invasive adenocarcinomas

previously diagnosed as atypical adenomatous hyperplasia, AIS or MIA during frozen section examination (14), these discordant results nevertheless indicate the need for caution in using the results of frozen section examination to decide on the extent of lung resection and intraoperative nodal assessment.

Spread through air spaces (STAS) is another important consideration. Kadota *et al.* triggered alarm when they reported significantly increased local recurrence in patients with lung adenocarcinomas of ≤ 2 cm who had undergone sublobar resections and whose specimens had STAS (15). Since then, many others have reported that the presence of STAS, whether understood as a true way of cancer dissemination or an artefact related to cell subtypes of intrinsically poor prognosis (16), is associated with worse prognosis in all cell types (17). There is currently no code for STAS in the tumour, node and metastasis (TNM) classification. Based on the anatomic extent of cancers, the TNM classification is supported by cytological or histologic confirmation of tumour extent: malignant cells in the pleural or pericardial fluids indicate M1a; in the bronchial secretions with no other evidence of tumour, TX; in the lymph nodes or bone marrow, as N0(i/mol+) and M0(i/mol+), respectively, the 'i' indicating their identification by morphological analysis, such as immunohistochemistry, and 'mol' indicating their identification by non-morphological tests, such as molecular analysis; finally, when found in pleural lavage fluid, the resection is deemed microscopically incomplete (R1cy+) (18). No code has yet been assigned to STAS, discussions are ongoing whether it should be a descriptor of the T or of the M component of the classification, whether it should be coded in a similar way to vascular invasion (V), lymphatic permeation (L) or perineural invasion (Pn), or whether STAS should be a qualifier of uncertain or incomplete resections. No decision has been made at the time of this writing, but there is every reason to think that STAS will have its place in the forthcoming 9th edition of the TNM classification.

Circulating cancer cells or tumour DNA (ctDNA) can be found in the blood stream, persistence or recurrence of which connotes a poor prognosis after treatment, including after radiotherapy or resection (19-23). This indication of minimal residual disease was not considered when IASLC definitions were published, but the final paragraph of that article stated that the definitions were not static and that they were subject to revision as new information was generated 'especially in the field of molecular biology, to identify residual disease'. Some have proposed that the

presence of cancer cells or ctDNA in the blood should be considered a new component of the TNM classification that should be added as B for blood—TNMB—with two categories: B0 (no cancer cells in the blood) and B1 (cancer cells in the blood) (24). Perhaps, it is too early to consider the presence of cancer cells in the blood as a criterion of incomplete resection or as a new component of the TNM classification, given the lack of universal availability even in developed countries, but it will be considered in future revisions of the classification and of the IASLC definitions of completeness of resection as more data becomes available and the test becomes more generally used in clinical practice.

Lee *et al.* raise the possibility of using radiologic/pathologic tumour characteristics to tailor the intraoperative nodal assessment in early lung cancers. However, the revision of the IASLC definitions should be more comprehensive and not limited to this one technical aspect of the lung cancer resection. The revision should take into account the new pathologic findings of local invasiveness, such as STAS, and the presence of circulating cancer cells or ctDNA. This is a natural progression: from macroscopic assessment and procedural requirements to refinements in the microscopic examination of the resected specimen and the assessment of minimal residual disease by means of blood-based 'liquid' biopsy. With the emerging evidence, the definitions of completeness of resection will evolve. Any revision must be thoughtful and evidence-based. Emerging biomarkers might minimize the uncertainty in determining the completeness of lung cancer resection. Until then, the prognostic value of the existing definitions having been widely validated in large multi-institutional datasets, the *status quo* seems appropriate (25-28).

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Translational Cancer Research*. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-2426/coif>). RUO has patents for a lymph node specimen collection kit; Board

Chair, Hope Foundation for Cancer Research; paid consultant for AstraZeneca, American Cancer Society, US National Cancer Institute, Tryptych Healthcare Partners. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Lee J, Hong YS, Cho J, et al. Reclassifying the International Association for the Study of Lung Cancer Residual Tumor Classification According to the Extent of Nodal Dissection for NSCLC: One Size Does Not Fit All. *J Thorac Oncol* 2022;17:890-9.
- Rami-Porta R, Wittekind C, Goldstraw P, et al. Complete resection in lung cancer surgery: proposed definition. *Lung Cancer* 2005;49:25-33.
- Wittekind C, Compton C, Quirke P, et al. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. *Cancer* 2009;115:3483-8.
- Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. *Cancer* 1995;75:2844-52.
- Travis WD, Brambilla E, Noguchi M, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. *J Thorac Oncol* 2011;6:244-85.
- Travis WD, Brambilla E, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, International Agency for Research on Cancer, 2015.
- Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. *Mod Pathol* 2011;24:653-64.
- Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. *J Thorac Oncol* 2011;6:1496-504.
- Moreira AL, Ocampo PSS, Xia Y, et al. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. *J Thorac Oncol* 2020;15:1599-610.
- He P, Yao G, Guan Y, et al. Diagnosis of lung adenocarcinoma in situ and minimally invasive adenocarcinoma from intraoperative frozen sections: an analysis of 136 cases. *J Clin Pathol* 2016;69:1076-80.
- Shima T, Kinoshita T, Sasaki N, et al. Feasibility of intraoperative diagnosis of lung adenocarcinoma in situ to avoid excessive resection. *J Thorac Dis* 2021;13:1338-46.
- Liu S, Wang R, Zhang Y, et al. Precise Diagnosis of Intraoperative Frozen Section Is an Effective Method to Guide Resection Strategy for Peripheral Small-Sized Lung Adenocarcinoma. *J Clin Oncol* 2016;34:307-13.
- Su H, Gu C, She Y, et al. Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma. *Transl Lung Cancer Res* 2021;10:32-44.
- Zhang Y, Deng C, Fu F, et al. Excellent Prognosis of Patients With Invasive Lung Adenocarcinomas During Surgery Misdiagnosed as Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, or Minimally Invasive Adenocarcinoma by Frozen Section. *Chest* 2021;159:1265-72.
- Kadota K, Nitadori JI, Sima CS, et al. Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. *J Thorac Oncol* 2015;10:806-14.
- Blaauwgeers H, Russell PA, Jones KD, et al. Pulmonary loose tumor tissue fragments and spread through air spaces (STAS): Invasive pattern or artifact? A critical review. *Lung Cancer* 2018;123:107-11.
- Jia M, Yu S, Gao H, et al. Spread Through Air Spaces (STAS) in Lung Cancer: A Multiple-Perspective and Update Review. *Cancer Manag Res* 2020;12:2743-52.
- Brierly JD, Gospodarowicz MK, Wittekind C. UICC

- TNM Classification of Malignant Tumours, 8th ed. Oxford, UK: Wiley Blackwell, 2017.
19. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. *Cancer Discov* 2017;7:1394-403.
 20. Ohara S, Suda K, Sakai K, et al. Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study. *Transl Lung Cancer Res* 2020;9:1915-23.
 21. Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. *J Clin Oncol* 2018;36:1631-41.
 22. Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment. *N Engl J Med* 2018;379:1754-65.
 23. Pellini B, Chaudhuri AA. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent. *J Clin Oncol* 2022;40:567-75.
 24. Yang M, Forbes ME, Bitting RL, et al. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? *Ann Oncol* 2018;29:311-23.
 25. Gagliasso M, Migliaretti G, Ardisson E. Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery. *Lung Cancer* 2017;111:124-30.
 26. Edwards JG, Chansky K, Van Schil P, et al. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. *J Thorac Oncol* 2020;15:344-59.
 27. Osarogiagbon RU, Faris NR, Stevens W, et al. Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization. *J Thorac Oncol* 2020;15:371-82.
 28. Yun JK, Lee GD, Choi S, et al. A Validation Study of the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients With pN2 NSCLC. *J Thorac Oncol* 2021;16:817-26.

Cite this article as: Rami-Porta R, Edwards JG, Osarogiagbon RU. Is it time to revise the International Association for the Study of Lung Cancer definitions of completeness of lung cancer resection? *Transl Cancer Res* 2022;11(12):4474-4478. doi: 10.21037/tcr-22-2426